News &amp; Updates

The use of mazdutide among adults with obesity results in a clinically significant weight reduction and improvements in cardiometabolic risk factors, with an acceptable safety profile, as shown in the phase 3 GLORY-2 trial presented at ADA 2026.

Mazdutide cuts weight in adults with obesity, T2D

19 Jun 2026

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

In a post hoc analysis of the phase III MAESTRO-NASH trial presented at ADA 2026, systemic thyroid function remained stable with resmetirom, supporting its extrahepatic safety in individuals with metabolic dysfunction-associated steatohepatitis (MASH).

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

Novel dual PDE3/PDE4 inhibitor shows promise in COPD

In the treatment of patients with chronic obstructive pulmonary disease (COPD), the investigational dual phosphodiesterase (PDE) 3 and 4 inhibitor TQC3721 helps improve lung function, according to a phase 2 PACER-II study.

Novel dual PDE3/PDE4 inhibitor shows promise in COPD

Satralizumab cuts relapse risk in MOGAD

Satralizumab reduces the risk of relapse by 68 percent in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), as shown in the phase III METEOROID study presented at AAN 2026.

Satralizumab cuts relapse risk in MOGAD

Fluvoxamine wins, metformin disappoints in long COVID fatigue

The antidepressant fluvoxamine reduces long COVID fatigue, whereas the antidiabetic agent metformin fails to outperform placebo in the randomized REVIVE-TOGETHER trial.

Fluvoxamine wins, metformin disappoints in long COVID fatigue

19 Jun 2026

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

18 Jun 2026 by

For individuals with type 2 diabetes (T2D) that is inadequately controlled by diet and exercise alone, once-weekly administration of the triple hormone receptor agonist retatrutide helps improve glycaemic control, and this benefit is accompanied by substantial weight reduction, as shown in the phase III TRANSCEND-T2D-1 study.

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

Switching between JAK inhibitors a feasible solution for severe alopecia areata

Patients with treatment-refractory alopecia areata (AA) may benefit from switching between Janus kinase inhibitors (JAKis), suggests a study.

Switching between JAK inhibitors a feasible solution for severe alopecia areata

Reduced RT plus chemo-immunotherapy feasible in older/frail NSCLC patients

18 Jun 2026 by

In older or frail patients with stage III non-small cell lung cancer (NSCLC), undergoing reduced radiotherapy (RT) followed by sequential chemo-immunotherapy results in survival outcomes similar to standard RT, indicating its utility in vulnerable populations, suggests a study.

Reduced RT plus chemo-immunotherapy feasible in older/frail NSCLC patients

18 Jun 2026

COVID-19 vaccine reduces emergency attendance, hospitalization in youths

Vaccination with BNT162b2 against SARS-CoV-2 infections has helped reduce accident and emergency (A&E) attendance and hospitalization among adolescents and children, reports a study.

COVID-19 vaccine reduces emergency attendance, hospitalization in youths

Updated ALIGN data boost atrasentan potential in IgAN

18 Jun 2026 by

Results from the final analysis of the phase III ALIGN trial continue to support the efficacy and safety of atrasentan for the treatment of IgA nephropathy (IgAN).

Updated ALIGN data boost atrasentan potential in IgAN